600976.SH
健民集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 27.58
+0.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 3.4B | 3.5B | 4.2B | 3.6B |
| Cost of Revenue | 1.3B | 1.4B | 1.8B | 2.3B | 2.1B |
| Gross Profit | 2.0B | 2.0B | 1.7B | 1.9B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 98.9M | 98.7M | 79.5M | 74.0M | 73.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 153.0M | 152.5M | 192.3M | 172.4M | 136.0M |
| Selling & Marketing Expense | 1.5B | 1.5B | 1.2B | 1.3B | 1.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.8B | 1.7B | 1.5B | 1.6B | 1.3B |
| Cost and Expenses | 3.1B | 3.1B | 3.4B | 3.9B | 3.4B |
| Operating Income (EBIT) | 364.1M | 391.3M | 396.8M | 573.9M | 442.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 363.8M | 391.1M | 392.6M | 571.1M | 437.9M |
| Income Tax Expense | 21.3M | 25.8M | 24.9M | 47.9M | 31.9M |
| Bottom Line | |||||
| Net Income | 337.4M | 359.8M | 362.2M | 521.5M | 408.1M |
| Earnings from Cont. Ops | 342.5M | 365.2M | 367.7M | 529.9M | 421.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 337.4M | 359.8M | 362.2M | 521.5M | 408.1M |
| Per Share | |||||
| Basic EPS | CN¥2.23 | CN¥2.37 | CN¥2.38 | CN¥3.41 | CN¥2.68 |
| Diluted EPS | CN¥2.23 | CN¥2.37 | CN¥2.38 | CN¥3.41 | CN¥2.68 |
| Revenue Per Share | CN¥22.15 | CN¥22.20 | CN¥23.03 | CN¥27.55 | CN¥23.91 |
| Shares | |||||
| Basic Shares Outstanding | 151.3M | 151.8M | 152.2M | 152.9M | 152.3M |
| Diluted Shares Outstanding | 151.3M | 151.8M | 152.2M | 152.9M | 152.3M |
| Profitability Metrics | |||||
| EBITDA | — | 455.6M | 461.0M | 625.6M | 490.2M |
| D&A | — | 64.3M | 64.2M | 51.7M | 48.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026